RALD
MCID: RSS025
MIFTS: 51

Ras-Associated Autoimmune Leukoproliferative Disorder (RALD)

Categories: Blood diseases, Genetic diseases, Immune diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Ras-Associated Autoimmune Leukoproliferative Disorder

MalaCards integrated aliases for Ras-Associated Autoimmune Leukoproliferative Disorder:

Name: Ras-Associated Autoimmune Leukoproliferative Disorder 57 11 73 38 71 75
Autoimmune Lymphoproliferative Syndrome Type 4 11 28 5 14
Rald 57 11 58 73
Alps4 57 11 73
Ras-Associated Autoimmune Leukoproliferative Disease 11 58
Autoimmune Lymphoproliferative Syndrome, Type Iv 57 73
Ras-Associated Autoimmune Lymphoproliferative Syndrome Type Iv, Somatic 57
Autoimmune Lymphoproliferative Syndrome Type Iv 11
Autoimmune Lymphoproliferative Syndrome 4 73
Alps Type Iv 11
Alps Type 4 11

Characteristics:


Inheritance:

Autosomal dominant 57

Prevelance:

Ras-Associated Autoimmune Leukoproliferative Disease: <1/1000000 (Worldwide) 58

Age Of Onset:

Ras-Associated Autoimmune Leukoproliferative Disease: Childhood,Infancy 58

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
onset in childhood
caused by somatic mutations


Classifications:

Orphanet: 58  
Rare haematological diseases
Rare immunological diseases


Summaries for Ras-Associated Autoimmune Leukoproliferative Disorder

OMIM®: 57 RAS-associated leukoproliferative disorder is characterized by lymphadenopathy, splenomegaly, and variable autoimmune phenomena, including autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, and neutropenia. Laboratory studies show an expansion of lymphocytes due to defective apoptosis, as well as significant autoantibodies. Some patients have recurrent infections, and there may be an increased risk of hematologic malignancy (summary by Oliveira, 2013 and Niemela et al., 2010). The disorder shows significant overlap with autoimmune lymphoproliferative syndrome (ALPS; 601859) and was originally designated ALPS IV. (614470) (Updated 08-Dec-2022)

MalaCards based summary: Ras-Associated Autoimmune Leukoproliferative Disorder, also known as autoimmune lymphoproliferative syndrome type 4, is related to leukemia, acute myeloid and hemolytic anemia. An important gene associated with Ras-Associated Autoimmune Leukoproliferative Disorder is NRAS (NRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. Affiliated tissues include monocytes, t cells and bone marrow, and related phenotypes are recurrent respiratory infections and splenomegaly

Orphanet: 58 RAS-associated autoimmune leukoproliferative disease (RALD) is a rare genetic disorder characterized by monocytosis, autoimmune cytopenias, lymphoproliferation, hepatosplenomegaly, and hypergammaglobulinemia.

UniProtKB/Swiss-Prot: 73 A disorder of apoptosis, characterized by chronic accumulation of non- malignant lymphocytes, defective lymphocyte apoptosis, and an increased risk for the development of hematologic malignancies.

Disease Ontology: 11 An autoimmune lymphoproliferative syndrome that has material basis in somatic mutation in the NRAS gene or the KRAS gene on chromosome 12p12.

Wikipedia: 75 RAS-associated autoimmune leukoproliferative disorder (RALD) is a rare genetic disorder of the immune... more...

Related Diseases for Ras-Associated Autoimmune Leukoproliferative Disorder

Diseases related to Ras-Associated Autoimmune Leukoproliferative Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 138)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 30.0 NRAS KRAS HRAS FASLG CASP8 BCL2L11
2 hemolytic anemia 29.9 TPP2 LRBA FASLG FAS CASP10
3 neuroblastoma 29.2 NRAS HRAS FASLG FAS CASP8 BCL2L11
4 lymphoproliferative syndrome 29.2 SH2D1A PRKCD NRAS LRBA FASLG FAS
5 autoimmune lymphoproliferative syndrome 28.1 SH2D1A PRKCD NRAS MAGT1 LRBA KRAS
6 juvenile myelomonocytic leukemia 10.4
7 splenomegaly 10.4
8 childhood leptomeningeal melanoma 10.4 NRAS HRAS
9 trachea carcinoma in situ 10.4 KRAS HRAS
10 common bile duct neoplasm 10.4 KRAS HRAS
11 malignant anus melanoma 10.4 NRAS HRAS
12 melanocytic nevus syndrome, congenital 10.4 NRAS HRAS
13 ampulla of vater benign neoplasm 10.4 KRAS HRAS
14 bladder urachal carcinoma 10.4 KRAS HRAS
15 hepatic flexure cancer 10.4 KRAS HRAS
16 vaginal carcinosarcoma 10.4 KRAS HRAS
17 urachus cancer 10.4 KRAS HRAS
18 adenosquamous lung carcinoma 10.4 KRAS HRAS
19 descending colon cancer 10.4 KRAS HRAS
20 chronic myelogenous leukemia, bcr-abl1 positive 10.4 NRAS KRAS
21 meningeal melanomatosis 10.4 NRAS HRAS
22 mucinous intrahepatic cholangiocarcinoma 10.4 KRAS HRAS
23 conjunctival nevus 10.4 NRAS HRAS
24 sigmoid neoplasm 10.4 KRAS HRAS
25 appendiceal neoplasm 10.3 KRAS HRAS
26 pancreatic mucinous cystadenoma 10.3 KRAS HRAS
27 central nervous system melanocytic neoplasm 10.3 NRAS HRAS
28 transverse colon cancer 10.3 KRAS HRAS
29 noonan syndrome-like disorder with loose anagen hair 1 10.3 KRAS HRAS
30 liver angiosarcoma 10.3 KRAS HRAS
31 ascending colon cancer 10.3 KRAS HRAS
32 mucinous lung adenocarcinoma 10.3 KRAS HRAS
33 malignant dermis tumor 10.3 NRAS HRAS
34 vulvar melanoma 10.3 NRAS HRAS
35 cystadenofibroma 10.3 KRAS HRAS
36 malignant skin fibrous histiocytoma 10.3 NRAS HRAS
37 endosalpingiosis 10.3 KRAS HRAS
38 malignant struma ovarii 10.3 NRAS HRAS
39 ovarian mucinous neoplasm 10.3 KRAS HRAS
40 appendix adenocarcinoma 10.3 KRAS HRAS
41 cervix melanoma 10.3 NRAS HRAS
42 large cell carcinoma with rhabdoid phenotype 10.3 KRAS HRAS
43 pancreatic signet ring cell adenocarcinoma 10.3 KRAS HRAS
44 cecum adenocarcinoma 10.3 KRAS HRAS
45 biliary tract benign neoplasm 10.3 KRAS HRAS
46 periampullary adenocarcinoma 10.3 KRAS HRAS
47 pancreatic acinar cell adenocarcinoma 10.3 KRAS HRAS
48 pleomorphic carcinoma 10.3 KRAS HRAS
49 small intestine adenocarcinoma 10.3 KRAS HRAS
50 acneiform dermatitis 10.3 NRAS KRAS HRAS

Graphical network of the top 20 diseases related to Ras-Associated Autoimmune Leukoproliferative Disorder:



Diseases related to Ras-Associated Autoimmune Leukoproliferative Disorder

Symptoms & Phenotypes for Ras-Associated Autoimmune Leukoproliferative Disorder

Human phenotypes related to Ras-Associated Autoimmune Leukoproliferative Disorder:

30 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 recurrent respiratory infections 30 Occasional (7.5%) HP:0002205
2 splenomegaly 30 HP:0001744
3 hepatomegaly 30 HP:0002240
4 hemolytic anemia 30 HP:0001878
5 leukemia 30 HP:0001909
6 lymphoma 30 HP:0002665
7 neutropenia 30 HP:0001875
8 pancytopenia 30 HP:0001876
9 lymphocytosis 30 HP:0100827
10 follicular hyperplasia 30 HP:0002729
11 autoimmune thrombocytopenia 30 HP:0001973
12 lymphoproliferative disorder 30 HP:0005523
13 monocytosis 30 HP:0012311
14 increased circulating antibody level 30 HP:0010702
15 decreased lymphocyte apoptosis 30 HP:0002731

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Abdomen Spleen:
splenomegaly

Hematology:
hemolytic anemia
pancytopenia
autoimmune thrombocytopenia

Respiratory:
recurrent respiratory infections (in some patients)

Abdomen Liver:
hepatomegaly

Immunology:
neutropenia
lymphadenopathy
monocytosis
recurrent infections (in some patients)
autoimmune disorders
more
Neoplasia:
increased risk of hematologic malignancy (1 patient)

Clinical features from OMIM®:

614470 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Ras-Associated Autoimmune Leukoproliferative Disorder:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.21 B3GNT2 BCL2L11 CARD11 CASP8 CTPS1 FAS
2 cellular MP:0005384 10.07 B3GNT2 BCL2L11 CARD11 CASP8 DOCK8 FAS
3 renal/urinary system MP:0005367 10.06 BCL2L11 CASP8 CTPS1 FAS FASLG HRAS
4 endocrine/exocrine gland MP:0005379 10.06 BCL2L11 CASP8 FAS FASLG HRAS KRAS
5 immune system MP:0005387 10.06 B3GNT2 BCL2L11 CARD11 CASP8 CTPS1 DOCK8
6 neoplasm MP:0002006 10.03 BCL2L11 CASP8 FAS FASLG HRAS KRAS
7 hematopoietic system MP:0005397 9.8 B3GNT2 BCL2L11 CARD11 CASP8 DOCK8 FAS
8 integument MP:0010771 9.32 BCL2L11 CARD11 CASP8 CTPS1 FAS FASLG

Drugs & Therapeutics for Ras-Associated Autoimmune Leukoproliferative Disorder

Search Clinical Trials, NIH Clinical Center for Ras-Associated Autoimmune Leukoproliferative Disorder

Genetic Tests for Ras-Associated Autoimmune Leukoproliferative Disorder

Genetic tests related to Ras-Associated Autoimmune Leukoproliferative Disorder:

# Genetic test Affiliating Genes
1 Autoimmune Lymphoproliferative Syndrome Type 4 28 KRAS NRAS

Anatomical Context for Ras-Associated Autoimmune Leukoproliferative Disorder

Organs/tissues related to Ras-Associated Autoimmune Leukoproliferative Disorder:

MalaCards : Monocytes, T Cells, Bone Marrow, Bone, Liver, Myeloid, Breast
ODiseA: Blood And Bone Marrow

Publications for Ras-Associated Autoimmune Leukoproliferative Disorder

Articles related to Ras-Associated Autoimmune Leukoproliferative Disorder:

(show top 50) (show all 65)
# Title Authors PMID Year
1
Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. 62 57 5
21079152 2011
2
Autoimmune lymphoproliferative syndrome-like disease with somatic KRAS mutation. 62 57 5
21063026 2011
3
NRAS mutation causes a human autoimmune lymphoproliferative syndrome. 57 5
17517660 2007
4
Oculoectodermal syndrome is a mosaic RASopathy associated with KRAS alterations. 5
25808193 2015
5
Structure-energy-based predictions and network modelling of RASopathy and cancer missense mutations. 5
24803665 2014
6
The expanding spectrum of the autoimmune lymphoproliferative syndromes. 57
24240292 2013
7
Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. 5
22683711 2012
8
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 5
22499344 2012
9
Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. 5
20949621 2011
10
Mosaicism for oncogenic G12D KRAS mutation associated with epidermal nevus, polycystic kidneys and rhabdomyosarcoma. 5
20805368 2010
11
Discordance for Schimmelpenning-Feuerstein-Mims syndrome in monochorionic twins supports the concept of a postzygotic mutation. 5
20949522 2010
12
Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia. 5
19775298 2009
13
Spontaneous improvement of hematologic abnormalities in patients having juvenile myelomonocytic leukemia with specific RAS mutations. 5
17332249 2007
14
Germline KRAS mutations cause Noonan syndrome. 5
16474405 2006
15
Clinicopathologic significance of the K-ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases. 5
7773929 1995
16
Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. 5
8439212 1993
17
N-ras gene point mutations in childhood acute lymphocytic leukemia correlate with a poor prognosis. 5
2407301 1990
18
The human c-Kirsten ras gene is activated by a novel mutation in codon 13 in the breast carcinoma cell line MDA-MB231. 5
3627975 1987
19
Amino-acid substitutions at codon 13 of the N-ras oncogene in human acute myeloid leukaemia. 5
2989702 1985
20
A case of refractory systemic lupus erythematosus with monocytosis exhibiting somatic KRAS mutation. 62
35361277 2022
21
Type I interferon activation in RAS-associated autoimmune leukoproliferative disease (RALD). 62
34455097 2021
22
Correlations between Retinal Arterial Morphometric Parameters and Neurodegeneration in Patients with Type 2 Diabetes Mellitus with No or Mild Diabetic Retinopathy. 62
33807881 2021
23
Clinical Spectrum of Ras-Associated Autoimmune Leukoproliferative Disorder (RALD). 62
33011939 2021
24
Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report. 62
33472608 2021
25
Differences and Similarities in Motives to Decrease Drinking, and to Drink in General Between Former and Current Heavy Drinkers-Implications for Changing Own Drinking Behaviour. 62
35095638 2021
26
Alcohol Use Behaviors and Reasons to Abstain From or Limit Drinking Among Medically Vulnerable Youth. 62
31985512 2020
27
Risk factors for recurrent autoimmune liver diseases after liver transplantation: A meta-analysis. 62
32443344 2020
28
Genetic heterogeneity of pediatric systemic lupus erythematosus with lymphoproliferation. 62
32443356 2020
29
Relative Average Look Duration and its Association with Neurophysiological Activity in Young Children with Autism Spectrum Disorder. 62
32024855 2020
30
RAS-associated Autoimmune Leukoproliferative disease (RALD) manifested with early-onset SLE-like syndrome: a case series of RALD in Chinese children. 62
31412876 2019
31
Superficial and Deep Cutaneous Involvement by RAS-Associated Autoimmunne Leukoproliferative Disease (RALD Cutis): A Histologic Mimicker of Histiocytoid Sweet Syndrome. 62
31335417 2019
32
A full-width half-maximum method to assess retinal vascular structural changes in patients with ischemic heart disease and microvascular anginga. 62
31358869 2019
33
Cutaneous involvement in an 8-year-old boy with Ras-associated autoimmune leucoproliferative disorder (RALD). 62
29908030 2018
34
Weekly Rituximab Followed by Monthly Rituximab Treatment for Autoimmune Disease Associated With RAS-associated Autoimmune Leukoproliferative Disease. 62
30080751 2018
35
Status of KRAS in iPSCs Impacts upon Self-Renewal and Differentiation Propensity. 62
29983389 2018
36
eRepo-ORP: Exploring the Opportunity Space to Combat Orphan Diseases with Existing Drugs. 62
29237557 2018
37
[Ras-associated autoimmune leukoproliferative disorder: a report of 2 cases and literature review]. 62
29141318 2017
38
T and B cell clonal expansion in Ras-associated lymphoproliferative disease (RALD) as revealed by next-generation sequencing. 62
28500641 2017
39
The importance of considering monogenic causes of autoimmunity: A somatic mutation in KRAS causing pediatric Rosai-Dorfman syndrome and systemic lupus erythematosus. 62
28043923 2017
40
Reprogramming of the retinoic acid pathway in decidualizing human endometrial stromal cells. 62
28253328 2017
41
Trajectories and correlates of reasons for abstaining or limiting drinking during adolescence. 62
26320735 2016
42
Somatic mosaicism for a NRAS mutation associates with disparate clinical features in RAS-associated leukoproliferative disease: a report of two cases. 62
25896945 2015
43
JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. 62
25691160 2015
44
Retinaldehyde dehydrogenase 1 deficiency inhibits PPARγ-mediated bone loss and marrow adiposity. 62
25064526 2014
45
Update on retinal vessel structure measurement with spectral-domain optical coherence tomography. 62
24976361 2014
46
Rapid atomic layer deposition of silica nanolaminates: synergistic catalysis of Lewis/Brønsted acid sites and interfacial interactions. 62
24126605 2013
47
Moderate vitamin A supplementation in obese mice regulates tissue factor and cytokine production in a sex-specific manner. 62
23850584 2013
48
Loss-of-function of the protein kinase C δ (PKCδ) causes a B-cell lymphoproliferative syndrome in humans. 62
23430113 2013
49
Deficiency of retinaldehyde dehydrogenase 1 induces BMP2 and increases bone mass in vivo. 62
23951127 2013
50
Autocrine function of aldehyde dehydrogenase 1 as a determinant of diet- and sex-specific differences in visceral adiposity. 62
22933113 2013

Variations for Ras-Associated Autoimmune Leukoproliferative Disorder

ClinVar genetic disease variations for Ras-Associated Autoimmune Leukoproliferative Disorder:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 KRAS NM_033360.4(KRAS):c.436G>C (p.Ala146Pro) SNV Pathogenic
375963 rs121913527 GRCh37: 12:25378562-25378562
GRCh38: 12:25225628-25225628
2 KRAS NM_004985.5(KRAS):c.101C>G (p.Pro34Arg) SNV Pathogenic
12590 rs104894366 GRCh37: 12:25398218-25398218
GRCh38: 12:25245284-25245284
3 NRAS NM_002524.5(NRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic
13901 rs121434596 GRCh37: 1:115258744-115258744
GRCh38: 1:114716123-114716123
4 KRAS NM_004985.5(KRAS):c.38G>A (p.Gly13Asp) SNV Pathogenic
12580 rs112445441 GRCh37: 12:25398281-25398281
GRCh38: 12:25245347-25245347
5 KRAS NM_004985.5(KRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic
12582 rs121913529 GRCh37: 12:25398284-25398284
GRCh38: 12:25245350-25245350
6 KRAS NM_004985.5(KRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic
45123 rs121913535 GRCh37: 12:25398282-25398282
GRCh38: 12:25245348-25245348
7 KRAS NM_004985.5(KRAS):c.458A>T (p.Asp153Val) SNV Pathogenic
12587 rs104894360 GRCh37: 12:25362838-25362838
GRCh38: 12:25209904-25209904
8 KRAS NM_033360.4(KRAS):c.355G>A (p.Asp119Asn) SNV Likely Pathogenic
40460 rs730880471 GRCh37: 12:25378643-25378643
GRCh38: 12:25225709-25225709
9 KRAS NM_033360.4(KRAS):c.112-5C>T SNV Uncertain Significance
626130 rs376520586 GRCh37: 12:25380351-25380351
GRCh38: 12:25227417-25227417
10 KRAS NM_004985.5(KRAS):c.451-5541A>G SNV Uncertain Significance
1028518 rs779951033 GRCh37: 12:25368386-25368386
GRCh38: 12:25215452-25215452

UniProtKB/Swiss-Prot genetic disease variations for Ras-Associated Autoimmune Leukoproliferative Disorder:

73
# Symbol AA change Variation ID SNP ID
1 NRAS p.Gly13Asp VAR_063084 rs121434596

Expression for Ras-Associated Autoimmune Leukoproliferative Disorder

Search GEO for disease gene expression data for Ras-Associated Autoimmune Leukoproliferative Disorder.

Pathways for Ras-Associated Autoimmune Leukoproliferative Disorder

Pathways related to Ras-Associated Autoimmune Leukoproliferative Disorder according to GeneCards Suite gene sharing:

(show top 50) (show all 100)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 TPP2 SH2D1A RALA PRKCD NRAS MAGT1
2
Show member pathways
13.88 BCL2L11 CASP10 CASP8 FAS FASLG HRAS
3
Show member pathways
13.81 TCF23 RALA PRKCD NRAS KRAS HRAS
4 13.78 RALA PRKCD NRAS KRAS HRAS FASLG
5
Show member pathways
13.67 PRKCD NRAS KRAS HRAS FASLG FAS
6
Show member pathways
13.45 RALA PRKCD NRAS KRAS HRAS FASLG
7
Show member pathways
13.34 RALA PRKCD NRAS KRAS HRAS FASLG
8
Show member pathways
13.26 TCF23 PRKCD NRAS KRAS HRAS FASLG
9
Show member pathways
12.98 NRAS KRAS HRAS FASLG BCL2L11
10
Show member pathways
12.95 PRKCD NRAS KRAS HRAS CARD11
11
Show member pathways
12.94 BCL2L11 CASP10 CASP8 FAS FASLG HRAS
12
Show member pathways
12.91 FASLG FAS CASP8 CASP10 BCL2L11
13
Show member pathways
12.9 RALA PRKCD NRAS KRAS HRAS
14
Show member pathways
12.89 PRKCD NRAS KRAS HRAS FASLG FAS
15
Show member pathways
12.87 NRAS KRAS HRAS FAS CASP8
16 12.87 RALA PRKCD NRAS KRAS HRAS
17
Show member pathways
12.84 NRAS KRAS HRAS FASLG FAS CASP8
18
Show member pathways
12.8 CASP8 HRAS KRAS NRAS PRKCD
19
Show member pathways
12.78 BCL2L11 HRAS KRAS NRAS PRKCD
20
Show member pathways
12.74 NRAS KRAS HRAS FASLG FAS CASP8
21
Show member pathways
12.71 PRKCD FASLG FAS CASP8 BCL2L11
22
Show member pathways
12.7 PRKCD NRAS KRAS HRAS FASLG
23
Show member pathways
12.68 PRKCD NRAS KRAS HRAS FASLG FAS
24
Show member pathways
12.67 PRKCD NRAS KRAS HRAS CASP8
25
Show member pathways
12.65 PRKCD HRAS FASLG FAS CASP8 CASP10
26
Show member pathways
12.64 FASLG FAS CASP8 CASP10 BCL2L11
27 12.59 SH2D1A FASLG FAS CARD11
28
Show member pathways
12.58 RALA NRAS KRAS HRAS
29
Show member pathways
12.53 BCL2L11 CASP8 HRAS KRAS NRAS PRKCD
30
Show member pathways
12.46 HRAS KRAS NRAS PRKCD
31
Show member pathways
12.43 HRAS KRAS NRAS PRKCD RALA
32
Show member pathways
12.4 FASLG FAS CASP8 CASP10
33
Show member pathways
12.4 PRKCD NRAS KRAS HRAS CASP8 CASP10
34
Show member pathways
12.4 PRKCD NRAS KRAS HRAS CASP8 CASP10
35
Show member pathways
12.39 FASLG FAS CASP8 BCL2L11
36
Show member pathways
12.39 FASLG FAS CASP8 CASP10
37
Show member pathways
12.38 CARD11 CASP8 HRAS KRAS NRAS PRKCD
38
Show member pathways
12.36 PRKCD NRAS KRAS HRAS
39
Show member pathways
12.35 PRKCD NRAS KRAS HRAS
40 12.32 PRKCD NRAS KRAS HRAS FASLG FAS
41
Show member pathways
12.29 PRKCD NRAS KRAS HRAS
42 12.27 RALA NRAS KRAS HRAS FASLG
43
Show member pathways
12.25 BCL2L11 HRAS KRAS NRAS
44
Show member pathways
12.25 PRKCD NRAS KRAS HRAS
45
Show member pathways
12.25 FASLG FAS CASP8 CASP10
46
Show member pathways
12.21 HRAS KRAS NRAS PRKCD
47
Show member pathways
12.2 FASLG FAS CASP8 CASP10
48
Show member pathways
12.18 NRAS KRAS HRAS BCL2L11
49
Show member pathways
12.16 NRAS KRAS HRAS BCL2L11
50
Show member pathways
12.16 HRAS KRAS NRAS PRKCD

GO Terms for Ras-Associated Autoimmune Leukoproliferative Disorder

Cellular components related to Ras-Associated Autoimmune Leukoproliferative Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 death-inducing signaling complex GO:0031264 9.46 FAS CASP8
2 ripoptosome GO:0097342 9.26 CASP8 CASP10
3 CD95 death-inducing signaling complex GO:0031265 9.1 FAS CASP8 CASP10

Biological processes related to Ras-Associated Autoimmune Leukoproliferative Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extrinsic apoptotic signaling pathway GO:0097191 9.73 FASLG FAS CASP8
2 B cell proliferation GO:0042100 9.63 PRKCD CTPS1 CARD11
3 necroptotic signaling pathway GO:0097527 9.62 FASLG FAS
4 regulation of apoptotic process GO:0042981 9.61 FAS CASP8 CASP10 CARD11 BCL2L11
5 Ras protein signal transduction GO:0007265 9.23 RALA NRAS KRAS HRAS

Molecular functions related to Ras-Associated Autoimmune Leukoproliferative Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 GDP binding GO:0019003 9.56 RALA NRAS KRAS HRAS
2 death effector domain binding GO:0035877 9.46 CASP8 CASP10
3 G protein activity GO:0003925 9.23 RALA NRAS KRAS HRAS

Sources for Ras-Associated Autoimmune Leukoproliferative Disorder

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....